The Opioid REMS And Pharma’s Reputation: Slow Uptake May Become Significant Vulnerability
This article was originally published in RPM Report
The ongoing review of the best regulatory strategies to limit harm from opioid pain therapies raises some dangerous themes at a difficult time for the biopharmaceutical industry.
You may also be interested in...
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.